[en] Peroxisome proliferator-activated receptors (PPARs) are well studied for their peripheral physiological and pathological impact, but they also play an important role for the pathogenesis of various disorders of the central nervous system (CNS) like multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's, and Parkinson's disease. The observation that PPARs are able to suppress the inflammatory response in peripheral macrophages and in several models of human autoimmune diseases lead to the idea that PPARs might be beneficial for CNS disorders possessing an inflammatory component. The neuroinflammatory response during the course of Alzheimer's disease (AD) is triggered by the neurodegeneration and the deposition of the beta-amyloid peptide in extracellular plaques. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been considered to delay the onset and reduce the risk to develop Alzheimer's disease, while they also directly activate PPARgamma. This led to the hypothesis that NSAID protection in AD may be partly mediated by PPARgamma. Several lines of evidence have supported this hypothesis, using AD-related transgenic cellular and animal models. Stimulation of PPARgamma receptors by synthetic agonist (thiazolidinediones) inducing anti-inflammatory, anti-amyloidogenic, and insulin sensitising effects may account for the observed effects. Several clinical trials already revealed promising results using PPAR agonists, therefore PPARs represent an attractive therapeutic target for the treatment of AD.
Disciplines :
Neurologie
Auteur, co-auteur :
Kummer, Markus P; Department of Neurology, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany
HENEKA, Michael ; Department of Neurology, University of Bonn, 53127 Bonn, Germany
Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocrine Reviews 1999 20 5 649 688
Michalik L., Auwerx J., Berger J. P., International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors Pharmacological Reviews 2006 58 4 726 741
Willson T. M., Lambert M. H., Kliewer S. A., Peroxisome proliferator-activated receptor γ and metabolic disease Annual Review of Biochemistry 2001 70 341 367
Barish G. D., Evans R. M., PPARs and LXRs: atherosclerosis goes nuclear Trends in Endocrinology and Metabolism 2004 15 4 158 165
Pascual G., Fong A. L., Ogawa S., A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR- γ Nature 2005 437 7059 759 763
Diradourian C., Girard J., Pégorier J.-P., Phosphorylation of PPARs: from molecular characterization to physiological relevance Biochimie 2005 87 1 33 38
McKay L. I., Cidlowski J. A., Molecular control of immune/inflammatory responses: interactions between nuclear factor- κ B and steroid receptor-signaling pathways Endocrine Reviews 1999 20 4 435 459
Daynes R. A., Jones D. C., Emerging roles of PPARs in inflammation and immunity Nature Reviews Immunology 2002 2 10 748 759
Ghisletti S., Huang W., Ogawa S., Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPAR γ Molecular Cell 2007 25 1 57 70
Ogawa S., Lozach J., Benner C., Molecular determinants of crosstalk between nuclear receptors and toll-like receptors Cell 2005 122 5 707 721
Krey G., Braissant O., L'Horset F., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay Molecular Endocrinology 1997 11 6 779 791
Bernando A., Minghetti L., PPAR- γ agonists as regulators of microglial activation and brain inflammation Current Pharmaceutical Design 2006 12 1 93 109
Keller J. M., Collet P., Bianchi A., Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease International Journal of Developmental Biology 2000 44 5 429 442
Mukherjee R., Jow L., Croston G. E., Paterniti J. R. Jr., Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR γ 2 versus PPAR γ 1 and activation with retinoid X receptor agonists and antagonists Journal of Biological Chemistry 1997 272 12 8071 8076
Auboeuf D., Rieusset J., Fajas L., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients Diabetes 1997 46 8 1319 1327
Palmer C. N. A., Hsu M.-H., Griffin K. J., Raucy J. L., Johnson E. F., Peroxisome proliferator activated receptor- α expression in human liver Molecular Pharmacology 1998 53 1 14 22
Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- α,-β, and-γ in the adult rat Endocrinology 1996 137 1 354 366
Moreno S., Farioli-vecchioli S., Cerù M. P., Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS Neuroscience 2004 123 1 131 145
Woods J. W., Tanen M., Figueroa D. J., Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons Brain Research 2003 975 1-2 10 21
Gofflot F., Chartoire N., Vasseur L., Systematic gene expression mapping clusters nuclear receptors according to their function in the brain Cell 2007 131 2 405 418
Basu-Modak S., Braissant O., Escher P., Desvergne B., Honegger P., Wahli W., Peroxisome proliferator-activated receptor β regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures Journal of Biological Chemistry 1999 274 50 35881 35888
Cimini A., Cristiano L., Colafarina S., PPAR γ -dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF) International Journal of Cancer 2005 117 6 923 933
Heneka M. T., Klockgether T., Feinstein D. L., Peroxisome proliferator-activated receptor- γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo The Journal of Neuroscience 2000 20 18 6862 6867
Inestrosa N. C., Godoy J. A., Quintanilla R. A., Koenig C. S., Bronfman M., Peroxisome proliferator-activated receptor γ is expressed in hippocampal neurons and its activation prevents β -amyloid neurodegeneration: role of Wnt signaling Experimental Cell Research 2005 304 1 91 104
Park K. S., Lee R. D., Kang S.-K., Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway Experimental Cell Research 2004 297 2 424 433
Smith S. A., Monteith G. R., Robinson J. A., Venkata N. G., May F. J., Roberts-Thomson S. J., Effect of the peroxisome proliferator-activated receptor β activator GW0742 in rat cultured cerebellar granule neurons Journal of Neuroscience Research 2004 77 2 240 249
Cimini A., Bernardo A., Cifone G., Di Muzio L., Di Loreto S., TNF α downregulates PPAR δ expression in oligodendrocyte progenitor cells: implications for demyelinating diseases Glia 2003 41 1 3 14
Saluja I., Granneman J. G., Skoff R. P., PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture Glia 2001 33 3 191 204
Cristiano L., Cimini A., Moreno S., Ragnelli A. M., Cerù M. P., Peroxisome proliferator-activated receptors (PPARs) and related transcription factors in differentiating astrocyte cultures Neuroscience 2005 131 3 577 587
Cullingford T. E., Bhakoo K., Peuchen S., Dolphin C. T., Patel R., Clark J. B., Distribution of mRNAs encoding the peroxisome proliferator-activated receptor α, β, and γ and the retinoid X receptor α, β, and γ in rat central nervous system Journal of Neurochemistry 1998 70 4 1366 1375
Farioli-Vecchioli S., Moreno S., Cerù M. P., Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system Journal of Neurocytology 2001 30 1 21 33
Tanzi R. E., Bertram L., Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective Cell 2005 120 4 545 555
Price D. L., Tanzi R. E., Borchelt D. R., Sisodia S. S., Alzheimer's disease: genetic studies and transgenic models Annual Review of Genetics 1998 32 461 493
Hüll M., Lieb K., Fiebich B. L., Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs Current Medicinal Chemistry 2002 9 1 83 88
Akiyama H., Barger S., Barnum S., Inflammation and Alzheimer's disease Neurobiology of Aging 2000 21 3 383 421
Sly L. M., Krzesicki R. F., Brashler J. R., Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease Brain Research Bulletin 2001 56 6 581 588
Heneka M. T., Wiesinger H., Dumitrescu-Ozimek L., Riederer P., Feinstein D. L., Klockgether T., Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease Journal of Neuropathology & Experimental Neurology 2001 60 9 906 916
Lee S. C., Zhao M., Hirano A., Dickson D. W., Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques Journal of Neuropathology & Experimental Neurology 1999 58 11 1163 1169
Vodovotz Y., Lucia M. S., Flanders K. C., Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease Journal of Experimental Medicine 1996 184 4 1425 1433
de la Monte S. M., Wands J. R., Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease Journal of Alzheimer's Disease 2006 9 2 167 181
Heneka M. T., Landreth G. E., Feinstein D. L., Role of peroxisome proliferator-activated receptor- γ in Alzheimer's disease Annals of Neurology 2001 49 2 276
Kielian T., Drew P. D., Effects of peroxisome proliferator-activated receptor- γ agonists on central nervous system inflammation Journal of Neuroscience Research 2003 71 3 315 325
Landreth G. E., Heneka M. T., Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease Neurobiology of Aging 2001 22 6 937 944
in 't Veld B. A., Ruitenberg A., Hofman A., Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease The New England Journal of Medicine 2001 345 21 1515 1521
Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A., Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs Journal of Biological Chemistry 1997 272 6 3406 3410
Heneka M. T., Feinstein D. L., Galea E., Gleichmann M., Wüllner U., Klockgether T., Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase Journal of Neuroimmunology 1999 100 1-2 156 168
Combs C. K., Johnson D. E., Karlo J. C., Cannady S. B., Landreth G. E., Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR γ agonists The Journal of Neuroscience 2000 20 2 558 567
Kim E. J., Kwon K. J., Park J.-Y., Lee S. H., Moon C.-H., Baik E. J., Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2 Brain Research 2002 941 1-2 1 10
Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martínez A., Perez-Castillo A., Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator- activated receptor γ activation Journal of Biological Chemistry 2005 280 22 21453 21462
Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., Tanayama S., Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys Arzneimittel-Forschung 1997 47 1 29 35
Yan Q., Zhang J., Liu H., Anti-inflammatory drug therapy alters β -amyloid processing and deposition in an animal model of Alzheimer's disease The Journal of Neuroscience 2003 23 20 7504 7509
Heneka M. T., Sastre M., Dumitrescu-Ozimek L., Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice Journal of Neuroinflammation 2005 2, article 22
Sastre M., Klockgether T., Heneka M. T., Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms International Journal of Developmental Neuroscience 2006 24 2-3 167 176
Sastre M., Dewachter I., Landreth G. E., Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor- γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β -secretase The Journal of Neuroscience 2003 23 30 9796 9804
Camacho I. E., Serneels L., Spittaels K., Merchiers P., Dominguez D., De Strooper B., Peroxisome proliferator-activated receptor γ induces a clearance mechanism for the amyloid- β peptide The Journal of Neuroscience 2004 24 48 10908 10917
Eriksen J. L., Sagi S. A., Smith T. E., NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo The Journal of Clinical Investigation 2003 112 3 440 449
Weggen S., Eriksen J. L., Das P., A subset of NSAIDs lower amyloidogenic A β 42 independently of cyclooxygenase activity Nature 2001 414 6860 212 216
Morihara T., Teter B., Yang F., Ibuprofen suppresses interleukin-1 β induction of pro-amyloidogenic α1 -antichymotrypsin to ameliorate β -amyloid (A β) pathology in Alzheimer's models Neuropsychopharmacology 2005 30 6 1111 1120
Lanz T. A., Fici G. J., Merchant K. M., Lack of specific amyloid- β (1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures Journal of Pharmacology and Experimental Therapeutics 2005 312 1 399 406
Fuentealba R. A., Farias G., Scheu J., Bronfman M., Marzolo M. P., Inestrosa N. C., Signal transduction during amyloid- β -peptide neurotoxicity: role in Alzheimer disease Brain Research Reviews 2004 47 1-3 275 289
Zhao X., Ou Z., Grotta J. C., Waxham N., Aronowski J., Peroxisome-proliferator-activated receptor-gamma (PPAR γ) activation protects neurons from NMDA excitotoxicity Brain Research 2006 1073-1074 460 469
Wada K., Nakajima A., Katayama K., Peroxisome proliferator-activated receptor γ -mediated regulation of neural stem cell proliferation and differentiation Journal of Biological Chemistry 2006 281 18 12673 12681
Pedersen W. A., McMillan P. J., Kulstad J. J., Leverenz J. B., Craft S., Haynatzki G. R., Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice Experimental Neurology 2006 199 2 265 273
Qiu W. Q., Folstein M. F., Insulin, insulin-degrading enzyme and amyloid- β peptide in Alzheimer's disease: review and hypothesis Neurobiology of Aging 2006 27 2 190 198
Risner M. E., Saunders A. M., Altman J. F. B., Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease The Pharmacogenomics Journal 2006 6 4 246 254
Chalimoniuk M., King-Pospisil K., Pedersen W. A., Arachidonic acid increases choline acetyltransferase activity in spinal cord neurons through a protein kinase C-mediated mechanism Journal of Neurochemistry 2004 90 3 629 636
Luchsinger J. A., Tang M.-X., Stern Y., Shea S., Mayeux R., Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort American Journal of Epidemiology 2001 154 7 635 641
Peila R., Rodriguez B. L., Launer L. J., Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study Diabetes 2002 51 4 1256 1262
Hamilton G., Proitsi P., Jehu L., Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPAR γ as susceptibility loci American Journal of Medical Genetics, Part B 2007 144 4 508 516
Stumvoll M., Häring H., The peroxisome proliferator-activated receptor- γ 2 Pro12Ala polymorphism Diabetes 2002 51 8 2341 2347
Altshuler D., Hirschhorn J. N., Klannemark M., The common PPAR γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes Nature Genetics 2000 26 1 76 80
Deeb S. S., Fajas L., Nemoto M., A Pro12Ala substitution in PPAR γ 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity Nature Genetics 1998 20 3 284 287
Frederiksen L., Brødbæk K., Fenger M., Studies of the Pro12Ala polymorphism of the PPAR- γ gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome The Journal of Clinical Endocrinology & Metabolism 2002 87 8 3989 3992
Scacchi R., Pinto A., Gambina G., Rosano A., Corbo R. M., The peroxisome proliferator-activated receptor gamma (PPAR- γ 2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians Brain Research 2007 1139 1 5
Watson G. S., Cholerton B. A., Reger M. A., Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study American Journal of Geriatric Psychiatry 2005 13 11 950 958
Strum J. C., Shehee R., Virley D., Rosiglitazone induces mitochondrial biogenesis in mouse brain Journal of Alzheimer's Disease 2007 11 1 45 51
Feinstein D. L., Spagnolo A., Akar C., Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochemical Pharmacology 2005 70 2 177 188
Craft S., Asthana S., Schellenberg G., Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender Neuroendocrinology 1999 70 2 146 152
Craft S., Asthana S., Schellenberg G., Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype Annals of the New York Academy of Sciences 2000 903 222 228
Kuusisto J., Koivisto K., Mykkänen L., Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study British Medical Journal 1997 315 7115 1045 1049
